Boston Scientific and Accenture Leverage Digital Health for Cardiovascular Patients
Boston Scientific Corp. and Accenture have teamed up to offer a cloud-based digital health product that is designed to help hospitals improve patient outcomes, reduce overall length of stay and readmission rates, and lower costs related to treating chronic cardiovascular diseases. The data-driven solution is currently being used on patients with heart failure, as the disease is one of the costliest to manage and generally results in longer hospital stays.
“We identified a 25% unnecessary heart failure readmissions rate, and therefore a definite need for better care coordination, supported by modern technology and processes that can decrease overall costs,” said Dr. Kari Niemelä, chief executive officer of Tampere Heart Hospital, in a press release. Located in Finland, Tampere Heart Hospital is one of two hospitals that Boston Scientific and Accenture worked with to assess the current state of care of heart failure patients, along with areas of improvement.
The Advantics Care Pathway Transformation solution focuses on pathway analytics (how a patient moves through the hospital system, including how long this takes), care management (how patients are diagnosed, treated and monitored), and patient engagement (how patients are educated, monitored and communicated with during and after their time in the hospital).
The companies plan to expand the digital health solution to other cardiovascular disease states in the future. The product will be made available to hospitals in the United Kingdom and Scandinavia, followed by pilot projects in Europe and the United States.
Related Articles
-
Rapid developments in healthcare technology, combined with improved data collection, pandemic pressures and increased consumer demand for tech-enabled and virtual health care, are fueling innovation and transformation in the digital health space.
-
“M.I.Tech is an innovator in nonvascular stent development, with product offerings that complement our existing stent portfolio.”
-
The COVID-19 pandemic exposed the necessity of virtual care and revealed its possibility as a more efficient means of administering treatment in an overwhelmed and understaffed infrastructure. Its fast-paced adoption highlighted the need for global standards and third-party certifications.
-
Digital therapeutics (DTx) have the potential to lower healthcare costs and improve patient compliance, outcomes and access to care. In the first part of this two-article series we look at the current and potential applications for this growing sector of…
